-
1
-
-
0026762669
-
Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
-
Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992; 117:234-42.
-
(1992)
Ann Intern Med
, vol.117
, pp. 234-242
-
-
Israili, Z.H.1
Hall, W.D.2
-
2
-
-
0025950044
-
Prevalence of persistent cough during long-term enalapril treatment: Controlled study versus nifedipine
-
Yeo WW, Foster G, Ramsay LE. Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine. Q J Med. 1991; 80:763-70.
-
(1991)
Q J Med
, vol.80
, pp. 763-770
-
-
Yeo, W.W.1
Foster, G.2
Ramsay, L.E.3
-
3
-
-
0029910150
-
Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors
-
Dicpinigaitis PV. Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1996; 30:1242-5.
-
(1996)
Ann Pharmacother
, vol.30
, pp. 1242-1245
-
-
Dicpinigaitis, P.V.1
-
4
-
-
0031765704
-
ACE inhibitor- Versus angiotensin II blocker-induced cough and angioedema
-
Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother. 1998; 32:1060-6.
-
(1998)
Ann Pharmacother
, vol.32
, pp. 1060-1066
-
-
Pylypchuk, G.B.1
-
5
-
-
0004106150
-
-
Wayne, PA: Astra Pharmaceuticals
-
Atacand package insert. Wayne, PA: Astra Pharmaceuticals; 1998.
-
(1998)
Atacand Package Insert
-
-
-
6
-
-
0004243460
-
-
Princeton, NJ: Bristol-Myers Squibb Company
-
Avapro package insert. Princeton, NJ: Bristol-Myers Squibb Company; 1998.
-
(1998)
Avapro Package Insert
-
-
-
7
-
-
0003782943
-
-
West Point, PA: Merck & Co.;
-
Cozaar package insert. West Point, PA: Merck & Co.; 1999.
-
(1999)
Cozaar Package Insert
-
-
-
8
-
-
0003878094
-
-
East Hanover, NJ: Novartis Pharmaceuticals
-
Diovan package insert. East Hanover, NJ: Novartis Pharmaceuticals; 1998.
-
(1998)
Diovan Package Insert
-
-
-
9
-
-
0003496154
-
-
Buffalo Grove, IL: Solvay Pharmaceuticals
-
Teveten package insert. Buffalo Grove, IL: Solvay Pharmaceuticals; 1999.
-
(1999)
Teveten Package Insert
-
-
-
10
-
-
0004327954
-
-
Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals
-
Micardis package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 1999.
-
(1999)
Micardis Package Insert
-
-
-
12
-
-
0028097788
-
Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms
-
Tanaka R, Kon V, Yoshioka T et al. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int. 1994; 45:537-43.
-
(1994)
Kidney Int
, vol.45
, pp. 537-543
-
-
Tanaka, R.1
Kon, V.2
Yoshioka, T.3
-
13
-
-
0030902115
-
Randomised trial of losartan versus captopril in patients over 65 with heart failure
-
Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet. 1997; 349:747-52.
-
(1997)
Lancet
, vol.349
, pp. 747-752
-
-
Pitt, B.1
Segal, R.2
Martinez, F.A.3
-
14
-
-
0027529918
-
Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans
-
Aldigier JC, Huang H, Dalmay F et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol. 1993; 21:289-95.
-
(1993)
J Cardiovasc Pharmacol
, vol.21
, pp. 289-295
-
-
Aldigier, J.C.1
Huang, H.2
Dalmay, F.3
-
15
-
-
0028258564
-
Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor
-
Rousseau MF, Konstam MA, Benedict CR et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 1994; 73:488-93.
-
(1994)
Am J Cardiol
, vol.73
, pp. 488-493
-
-
Rousseau, M.F.1
Konstam, M.A.2
Benedict, C.R.3
-
16
-
-
0027538401
-
Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications
-
Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens Suppl. 1993; 11:S13-8.
-
(1993)
J Hypertens Suppl
, vol.11
-
-
Dzau, V.J.1
Sasamura, H.2
Hein, L.3
-
17
-
-
0033341628
-
Practical considerations of the pharmacology of angiotensin receptor blockers
-
McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol. 1999; 39:547-59.
-
(1999)
J Clin Pharmacol
, vol.39
, pp. 547-559
-
-
McConnaughey, M.M.1
McConnaughey, J.S.2
Ingenito, A.J.3
-
18
-
-
0027162040
-
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects
-
Burnier M, Rutschmann B, Nussberger J et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993; 22:339-47.
-
(1993)
Hypertension
, vol.22
, pp. 339-347
-
-
Burnier, M.1
Rutschmann, B.2
Nussberger, J.3
-
19
-
-
0026527261
-
Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects
-
Nakashima M, Uematsu T, Kosuge K et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992; 42:333-5.
-
(1992)
Eur J Clin Pharmacol
, vol.42
, pp. 333-335
-
-
Nakashima, M.1
Uematsu, T.2
Kosuge, K.3
-
20
-
-
0029061433
-
Effects of losartan on a background of hydrochlorothiazide in patients with hypertension
-
Soffer BA, Wright JT Jr, Pratt JH et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995; 26:112-7.
-
(1995)
Hypertension
, vol.26
, pp. 112-117
-
-
Soffer, B.A.1
Wright Jr., J.T.2
Pratt, J.H.3
-
21
-
-
0032558158
-
Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients
-
Minghelli G, Seydoux C, Goy JJ et al. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation. 1998; 66:268-71.
-
(1998)
Transplantation
, vol.66
, pp. 268-271
-
-
Minghelli, G.1
Seydoux, C.2
Goy, J.J.3
-
22
-
-
0032578295
-
Uric acid as an independent risk factor in the treatment of hypertension
-
Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet. 1998; 352:670-1.
-
(1998)
Lancet
, vol.352
, pp. 670-671
-
-
Ward, H.J.1
-
23
-
-
0033005975
-
Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease
-
Johnson RJ, Kivlighn SD, Kim YG et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999; 33:225-34.
-
(1999)
Am J Kidney Dis
, vol.33
, pp. 225-234
-
-
Johnson, R.J.1
Kivlighn, S.D.2
Kim, Y.G.3
-
24
-
-
0032722880
-
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia
-
Shahinfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999; 56:1879-85.
-
(1999)
Kidney Int
, vol.56
, pp. 1879-1885
-
-
Shahinfar, S.1
Simpson, R.L.2
Carides, A.D.3
-
25
-
-
0027469656
-
Blood pressure, systolic and diastolic, and cardiovascular risks. US population data
-
Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993; 153:598-615.
-
(1993)
Arch Intern Med
, vol.153
, pp. 598-615
-
-
Stamler, J.1
Stamler, R.2
Neaton, J.D.3
-
26
-
-
0030750293
-
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
-
Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997; 54:299-311.
-
(1997)
Drugs
, vol.54
, pp. 299-311
-
-
Markham, A.1
Goa, K.L.2
-
27
-
-
0030694110
-
Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
-
Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs. 1997; 54:885-902.
-
(1997)
Drugs
, vol.54
, pp. 885-902
-
-
Gillis, J.C.1
Markham, A.2
-
28
-
-
0030722238
-
Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker
-
Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens. 1997; 11(suppl 2):S91-5.
-
(1997)
J Hum Hypertens
, vol.11
, Issue.2 SUPPL.
-
-
Sever, P.1
-
30
-
-
0032923579
-
Clinical efficacy of eprosartan
-
Weber M. Clinical efficacy of eprosartan. Pharmacotherapy. 1999; 19:95S-101S.
-
(1999)
Pharmacotherapy
, vol.19
-
-
Weber, M.1
-
31
-
-
0031882729
-
The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
-
Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998; 7:53-9.
-
(1998)
Blood Press
, vol.7
, pp. 53-59
-
-
Andersson, O.K.1
Neldam, S.2
-
32
-
-
0031800774
-
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators
-
Kassler-Taub K, Littlejohn T, Elliott W et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens. 1998; 11:445-53.
-
(1998)
Am J Hypertens
, vol.11
, pp. 445-453
-
-
Kassler-Taub, K.1
Littlejohn, T.2
Elliott, W.3
-
33
-
-
0031901366
-
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators
-
Oparil S, Guthrie R, Lewin AJ et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther. 1998; 20:398-409.
-
(1998)
Clin Ther
, vol.20
, pp. 398-409
-
-
Oparil, S.1
Guthrie, R.2
Lewin, A.J.3
-
34
-
-
0034030466
-
Angiotensin II antagonists for hypertension: Are there differences in efficacy?
-
Conlin PR, Spence JD, Williams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000; 13:418-26.
-
(2000)
Am J Hypertens
, vol.13
, pp. 418-426
-
-
Conlin, P.R.1
Spence, J.D.2
Williams, B.3
-
35
-
-
0033034404
-
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
-
Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353:611-6.
-
(1999)
Lancet
, vol.353
, pp. 611-616
-
-
Hansson, L.1
Lindholm, L.H.2
Niskanen, L.3
-
36
-
-
0032511601
-
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
-
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20.
-
(1998)
BMJ
, vol.317
, pp. 713-720
-
-
-
37
-
-
0031944128
-
Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
-
Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603.
-
(1998)
Diabetes Care
, vol.21
, pp. 597-603
-
-
Tatti, P.1
Pahor, M.2
Byington, R.P.3
-
38
-
-
0032485350
-
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
-
Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-52.
-
(1998)
N Engl J Med
, vol.338
, pp. 645-652
-
-
Estacio, R.O.1
Jeffers, B.W.2
Hiatt, W.R.3
-
39
-
-
0028848537
-
A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - The GLANT study
-
Study Group on Long-term Antihypertensive Therapy. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - the GLANT study. Hypertens Res. 1995; 18:235-44.
-
(1995)
Hypertens Res
, vol.18
, pp. 235-244
-
-
-
40
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients
-
Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000; 342:145-53.
-
(2000)
N Engl J Med
, vol.342
, pp. 145-153
-
-
-
41
-
-
0032436072
-
Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy
-
Benz JR, Black HR, Graff A et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998; 12:861-6.
-
(1998)
J Hum Hypertens
, vol.12
, pp. 861-866
-
-
Benz, J.R.1
Black, H.R.2
Graff, A.3
-
42
-
-
0028942349
-
Blood pressure effects of the angiotensin II receptor blocker, losartan
-
Weber MA, Byyny RL, Pratt JH et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995; 155:405-11.
-
(1995)
Arch Intern Med
, vol.155
, pp. 405-411
-
-
Weber, M.A.1
Byyny, R.L.2
Pratt, J.H.3
-
43
-
-
0030040951
-
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components
-
MacKay JH, Arcuri KE, Goldberg AI et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med. 1996; 156:278-85.
-
(1996)
Arch Intern Med
, vol.156
, pp. 278-285
-
-
MacKay, J.H.1
Arcuri, K.E.2
Goldberg, A.I.3
-
44
-
-
0028874530
-
Losartan potassium as initial therapy in patients with severe hypertension
-
Dunlay MC, Fitzpatrick V, Chrysant S et al. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens. 1995; 9:861-7.
-
(1995)
J Hum Hypertens
, vol.9
, pp. 861-867
-
-
Dunlay, M.C.1
Fitzpatrick, V.2
Chrysant, S.3
-
46
-
-
0028865295
-
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders
-
Fyhrquist F, Metsarinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995;9(suppl 5):S19-24.
-
(1995)
J Hum Hypertens
, vol.9
, Issue.5 SUPPL.
-
-
Fyhrquist, F.1
Metsarinne, K.2
Tikkanen, I.3
-
47
-
-
0021863924
-
Global cardiac remodeling after acute myocardial infarction: A study in the rat model
-
Weisman HF, Bush DE, Mannisi JA et al. Global cardiac remodeling after acute myocardial infarction: a study in the rat model. J Am Coll Cardiol. 1985; 5:1355-62.
-
(1985)
J Am Coll Cardiol
, vol.5
, pp. 1355-1362
-
-
Weisman, H.F.1
Bush, D.E.2
Mannisi, J.A.3
-
48
-
-
0025978369
-
Cellular basis of chronic ventricular remodeling after myocardial infarction in rats
-
Olivetti G, Capasso JM, Meggs LG et al. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res. 1991; 68:856-69.
-
(1991)
Circ Res
, vol.68
, pp. 856-869
-
-
Olivetti, G.1
Capasso, J.M.2
Meggs, L.G.3
-
49
-
-
0022536391
-
Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion
-
McKay RG, Pfeffer MA, Pasternak RC et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986; 74:693-702.
-
(1986)
Circulation
, vol.74
, pp. 693-702
-
-
McKay, R.G.1
Pfeffer, M.A.2
Pasternak, R.C.3
-
50
-
-
0029990688
-
The renin-angiotensin system in left ventricular remodeling
-
Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 1996; 77:8C-16C.
-
(1996)
Am J Cardiol
, vol.77
-
-
Blaufarb, I.S.1
Sonnenblick, E.H.2
-
51
-
-
13344259975
-
Ventricular remodeling
-
Maisch B. Ventricular remodeling. Cardiology. 1996; 87(suppl 1):2-10.
-
(1996)
Cardiology
, vol.87
, Issue.1 SUPPL.
, pp. 2-10
-
-
Maisch, B.1
-
52
-
-
0028840484
-
Effect of angiotensin II blockade on cardiac hypertrophy and remodeling: A review
-
Dalhof B. Effect of angiotensin II blockade on cardiac hypertrophy and remodeling: a review. J Hum Hypertens. 1995; 9(suppl 5):S37-44.
-
(1995)
J Hum Hypertens
, vol.9
, Issue.5 SUPPL.
-
-
Dalhof, B.1
-
53
-
-
0024221113
-
Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study
-
Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs. 1988; 35(suppl 5):1-5.
-
(1988)
Drugs
, vol.35
, Issue.5 SUPPL.
, pp. 1-5
-
-
Levy, D.1
-
54
-
-
0026517517
-
Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
-
Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992; 5:95-110.
-
(1992)
Am J Hypertens
, vol.5
, pp. 95-110
-
-
Dahlof, B.1
Pennert, K.2
Hansson, L.3
-
55
-
-
0031908811
-
Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
-
Schmieder RE, Schlaich MP, Klingbeil AU et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998; 13: 564-9.
-
(1998)
Nephrol Dial Transplant
, vol.13
, pp. 564-569
-
-
Schmieder, R.E.1
Schlaich, M.P.2
Klingbeil, A.U.3
-
56
-
-
0031721061
-
Regression of left ventricular hypertrophy in hypertension: Changing patterns with successive metaanalyses
-
Jennings G, Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive metaanalyses. J Hypertens Suppl. 1998; 16:S29-34.
-
(1998)
J Hypertens Suppl
, vol.16
-
-
Jennings, G.1
Wong, J.2
-
57
-
-
0032983534
-
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction
-
Sander G, McKinnie JJ, Greenberg SS et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Prog Cardiovasc Dis. 1999; 41:265-300.
-
(1999)
Prog Cardiovasc Dis
, vol.41
, pp. 265-300
-
-
Sander, G.1
McKinnie, J.J.2
Greenberg, S.S.3
-
58
-
-
0023266532
-
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
-
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-35.
-
(1987)
N Engl J Med
, vol.316
, pp. 1429-1435
-
-
-
59
-
-
0025913812
-
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
-
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325:293-302.
-
(1991)
N Engl J Med
, vol.325
, pp. 293-302
-
-
-
60
-
-
0026785561
-
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
-
SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-91.
-
(1992)
N Engl J Med
, vol.327
, pp. 685-691
-
-
-
61
-
-
0028798758
-
Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group
-
Crozier IG, Ikram H, Awan N et al. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation. 1995; 91:691-7.
-
(1995)
Circulation
, vol.91
, pp. 691-697
-
-
Crozier, I.G.1
Ikram, H.2
Awan, N.3
-
62
-
-
0027158296
-
Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs
-
Richard V, Berdeaux A, Giudicelli JF. Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs. J Cardiovasc Pharmacol. 1993; 22:52-7.
-
(1993)
J Cardiovasc Pharmacol
, vol.22
, pp. 52-57
-
-
Richard, V.1
Berdeaux, A.2
Giudicelli, J.F.3
-
63
-
-
0027379394
-
Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
-
Gottlieb SS, Dickstein K, Fleck E et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993; 88:1602-9.
-
(1993)
Circulation
, vol.88
, pp. 1602-1609
-
-
Gottlieb, S.S.1
Dickstein, K.2
Fleck, E.3
-
64
-
-
0000472711
-
Angiotensin II-mediated cardiac hypertrophy in adult rats
-
Abstract
-
Baker KM, Dostal DE, Chernin SC et al. Angiotensin II-mediated cardiac hypertrophy in adult rats. J Cell Biochem. 1991; 15C:167. Abstract.
-
(1991)
J Cell Biochem
, vol.15 C
, pp. 167
-
-
Baker, K.M.1
Dostal, D.E.2
Chernin, S.C.3
-
65
-
-
4243965522
-
Effects of the AT1 receptor antagonist losartan on angiotensin II induced hypertrophy of rat cardiomyocytes
-
Abstract
-
Murphy DD, Shepard J, Smith SC et al. Effects of the AT1 receptor antagonist losartan on angiotensin II induced hypertrophy of rat cardiomyocytes. FASEB J. 1992; 6:A1261. Abstract.
-
(1992)
FASEB J
, vol.6
-
-
Murphy, D.D.1
Shepard, J.2
Smith, S.C.3
-
66
-
-
0029102699
-
Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure
-
Dickstein K, Chang P, Willenheimer R et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995; 26:438-45.
-
(1995)
J Am Coll Cardiol
, vol.26
, pp. 438-445
-
-
Dickstein, K.1
Chang, P.2
Willenheimer, R.3
-
67
-
-
0030881016
-
Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators
-
Lang RM, Elkayam U, Yellen LG et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol. 1997; 30:983-91.
-
(1997)
J Am Coll Cardiol
, vol.30
, pp. 983-991
-
-
Lang, R.M.1
Elkayam, U.2
Yellen, L.G.3
-
68
-
-
0001545029
-
Irbesartan compared with lisinopril in patients with mild to moderate heart failure
-
Abstract
-
Vijay N, Alhaddad IA, Marty DD et al. Irbesartan compared with lisinopril in patients with mild to moderate heart failure. J Am Coll Cardiol. 1998; 31(suppl A):68A. Abstract.
-
(1998)
J Am Coll Cardiol
, vol.31
, Issue.SUPPL. A
-
-
Vijay, N.1
Alhaddad, I.A.2
Marty, D.D.3
-
69
-
-
0034612118
-
Effect of losartan compared with captoptril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study Elite II
-
Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captoptril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study Elite II. Lancet. 2000; 355:1582-7.
-
(2000)
Lancet
, vol.355
, pp. 1582-1587
-
-
Pitt, B.1
Poole-Wilson, P.A.2
Segal, R.3
-
70
-
-
0034074905
-
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin converting enzyme inhibitors
-
Granger C, Ertl G, Kuch J et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin converting enzyme inhibitors. Am Heart J. 2000; 139:609-17.
-
(2000)
Am Heart J
, vol.139
, pp. 609-617
-
-
Granger, C.1
Ertl, G.2
Kuch, J.3
-
71
-
-
0031028695
-
Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR
-
Nunez E, Hosoya K, Susic D et al. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension. 1997; 29:519-24.
-
(1997)
Hypertension
, vol.29
, pp. 519-524
-
-
Nunez, E.1
Hosoya, K.2
Susic, D.3
-
72
-
-
0031934185
-
Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats
-
Richer C, Bruneval P, Menard J et al. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension. 1998; 31:692-8.
-
(1998)
Hypertension
, vol.31
, pp. 692-698
-
-
Richer, C.1
Bruneval, P.2
Menard, J.3
-
73
-
-
0029083653
-
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
-
Azizi M, Chatellier G, Guyene TT et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995; 92:825-34.
-
(1995)
Circulation
, vol.92
, pp. 825-834
-
-
Azizi, M.1
Chatellier, G.2
Guyene, T.T.3
-
74
-
-
0031028895
-
Additive effects of losartan and enalapril on blood pressure and plasma active renin
-
Azizi M, Guyene TT, Chatellier G et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension. 1997; 29:634-40.
-
(1997)
Hypertension
, vol.29
, pp. 634-640
-
-
Azizi, M.1
Guyene, T.T.2
Chatellier, G.3
-
75
-
-
0031781441
-
Safety, tolerability, and neurohormonal changes of the combination of captopril plus losartan in the early postinfarction period: A pilot study
-
Di Pasquale P, Bucca V, Scalzo S et al. Safety, tolerability, and neurohormonal changes of the combination of captopril plus losartan in the early postinfarction period: a pilot study. Cardiovasc Drugs Ther. 1998; 12:211-6.
-
(1998)
Cardiovasc Drugs Ther
, vol.12
, pp. 211-216
-
-
Di Pasquale, P.1
Bucca, V.2
Scalzo, S.3
-
76
-
-
0000465226
-
Combined treatment with losartan and enalapril vs enalapril on neurohormonal activation in patients with heart failure
-
Abstract
-
Pitt B, Dickstein K, Benedict C et al. Combined treatment with losartan and enalapril vs enalapril on neurohormonal activation in patients with heart failure. Circulation. 1996; 94:1-428. Abstract.
-
(1996)
Circulation
, vol.94
, pp. 1-428
-
-
Pitt, B.1
Dickstein, K.2
Benedict, C.3
-
77
-
-
0030658003
-
Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure
-
Hamroff G, Blaufarb I, Mancini D et al. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol. 1997; 30:533-6.
-
(1997)
J Cardiovasc Pharmacol
, vol.30
, pp. 533-536
-
-
Hamroff, G.1
Blaufarb, I.2
Mancini, D.3
-
78
-
-
0000465227
-
Hemodynamic response to AT1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure. Valsartan Study Group
-
Abstract
-
Baruch L, Anand IS, Judd DL et al. Hemodynamic response to AT1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure. Valsartan Study Group. Circulation. 1996; 94(suppl 1):I-428. Abstract.
-
(1996)
Circulation
, vol.94
, Issue.1 SUPPL.
-
-
Baruch, L.1
Anand, I.S.2
Judd, D.L.3
-
79
-
-
0000830642
-
Angiotensin II receptor blockade combined to ACE inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure
-
Abstract
-
Tocchi M, Rosanio S, Anzuini A et al. Angiotensin II receptor blockade combined to ACE inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure. J Am Coll Cardiol. 1998; 31(suppl A):188A. Abstract.
-
(1998)
J Am Coll Cardiol
, vol.31
, Issue.SUPPL. A
-
-
Tocchi, M.1
Rosanio, S.2
Anzuini, A.3
-
80
-
-
0001545027
-
Irbesartan combined with conventional therapy, including angiotensin converting enzyme inhibitors, in heart failure. Irbesartan Heart Failure Group
-
Abstract
-
Tonkon M, Awan N, Niazi I et al. Irbesartan combined with conventional therapy, including angiotensin converting enzyme inhibitors, in heart failure. Irbesartan Heart Failure Group. J Am Coll Cardiol. 1998; 31(suppl A):188A. Abstract.
-
(1998)
J Am Coll Cardiol
, vol.31
, Issue.SUPPL. A
-
-
Tonkon, M.1
Awan, N.2
Niazi, I.3
-
81
-
-
4244148359
-
Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin-converting enzyme inhibition
-
Abstract
-
Hamroff G, Blaufarb I, Mancini D et al. Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 1998; 31(suppl A):188A. Abstract.
-
(1998)
J Am Coll Cardiol
, vol.31
, Issue.SUPPL. A
-
-
Hamroff, G.1
Blaufarb, I.2
Mancini, D.3
-
82
-
-
0033533456
-
Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. the RESOLVD Pilot Study Investigators
-
McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999; 100:1056-64.
-
(1999)
Circulation
, vol.100
, pp. 1056-1064
-
-
McKelvie, R.S.1
Yusuf, S.2
Pericak, D.3
-
83
-
-
0002839619
-
The Valsartan Heart Failure Trial (Val-HeFT)
-
Paper presented New Orleans, LA; Nov
-
Cohn JN. The Valsartan Heart Failure Trial (Val-HeFT). Paper presented at American Heart Association Scientific Sessions 2000. New Orleans, LA; Nov 2000.
-
(2000)
American Heart Association Scientific Sessions 2000
-
-
Cohn, J.N.1
-
84
-
-
0026786643
-
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators
-
Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327:669-77.
-
(1992)
N Engl J Med
, vol.327
, pp. 669-677
-
-
Pfeffer, M.A.1
Braunwald, E.2
Moye, L.A.3
-
85
-
-
0028273258
-
GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
-
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343:1115-22.
-
(1994)
Lancet
, vol.343
, pp. 1115-1122
-
-
-
86
-
-
0028862783
-
Discovery of losartan, the first angiotensin II receptor antagonist
-
Timmermans PB, Duncia JV, Carini DJ et al. Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens. 1995; 9(suppl 5):S3-18.
-
(1995)
J Hum Hypertens
, vol.9
, Issue.5 SUPPL.
-
-
Timmermans, P.B.1
Duncia, J.V.2
Carini, D.J.3
-
87
-
-
0025028032
-
Prostaglandins, angiotensin II, and proteinuria
-
Dunn MJ. Prostaglandins, angiotensin II, and proteinuria. Nephron. 1990; 55(suppl 1):30-7.
-
(1990)
Nephron
, vol.55
, Issue.1 SUPPL.
, pp. 30-37
-
-
Dunn, M.J.1
-
88
-
-
0027522956
-
Angiotensin-converting enzyme inhibitors in diabetic nephropathy
-
Melchoir WR, Bindlish V, Jaber LA. Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother. 1993; 27:344-50.
-
(1993)
Ann Pharmacother
, vol.27
, pp. 344-350
-
-
Melchoir, W.R.1
Bindlish, V.2
Jaber, L.A.3
-
89
-
-
0028960065
-
Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects
-
Burnier M, Hagman M, Nussberger J et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension. 1995; 25:602-9.
-
(1995)
Hypertension
, vol.25
, pp. 602-609
-
-
Burnier, M.1
Hagman, M.2
Nussberger, J.3
-
90
-
-
0027972824
-
Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: Effects on renal function
-
Jover B, Mimran A. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens Suppl. 1994; 12:S3-9.
-
(1994)
J Hypertens Suppl
, vol.12
-
-
Jover, B.1
Mimran, A.2
-
91
-
-
0029069447
-
Prevention and treatment of the complications of diabetes mellitus
-
Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 1995; 332: 1210-7.
-
(1995)
N Engl J Med
, vol.332
, pp. 1210-1217
-
-
Clark Jr., C.M.1
Lee, D.A.2
-
92
-
-
0029116325
-
Prevention and treatment of diabetic nephropathy
-
Foote EF. Prevention and treatment of diabetic nephropathy. Am J Health Syst Pharm. 1995; 52:1781-92.
-
(1995)
Am J Health Syst Pharm
, vol.52
, pp. 1781-1792
-
-
Foote, E.F.1
-
93
-
-
0023175729
-
Effect of antihypertensive treatment on kidney function in diabetic nephropathy
-
Parving HH, Andersen AR, Smidt UM et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J. 1987; 294:1443-7.
-
(1987)
Br Med J
, vol.294
, pp. 1443-1447
-
-
Parving, H.H.1
Andersen, A.R.2
Smidt, U.M.3
-
94
-
-
0027160570
-
Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy
-
Parving HH, Smidt UM, Hommel E et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis. 1993; 22:188-95.
-
(1993)
Am J Kidney Dis
, vol.22
, pp. 188-195
-
-
Parving, H.H.1
Smidt, U.M.2
Hommel, E.3
-
95
-
-
0028011891
-
Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group
-
Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994; 271:275-9.
-
(1994)
JAMA
, vol.271
, pp. 275-279
-
-
Viberti, G.1
Mogensen, C.E.2
Groop, L.C.3
-
96
-
-
0027517659
-
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
-
Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456-62.
-
(1993)
N Engl J Med
, vol.329
, pp. 1456-1462
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Bain, R.P.3
-
97
-
-
0026778853
-
Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis
-
Chan JCN, Cockram CS, Nicholls MG et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ. 1992; 305:981-5.
-
(1992)
BMJ
, vol.305
, pp. 981-985
-
-
Jcn, C.1
Cockram, C.S.2
Nicholls, M.G.3
-
98
-
-
0027517013
-
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
-
Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993; 118:577-81.
-
(1993)
Ann Intern Med
, vol.118
, pp. 577-581
-
-
Ravid, M.1
Savin, H.2
Jutrin, I.3
-
99
-
-
0030056947
-
Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus. A 7-year follow-up study
-
Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996; 156:286-9.
-
(1996)
Arch Intern Med
, vol.156
, pp. 286-289
-
-
Ravid, M.1
Lang, R.2
Rachmani, R.3
-
100
-
-
0027049331
-
Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
-
Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993; 118:129-38.
-
(1993)
Ann Intern Med
, vol.118
, pp. 129-138
-
-
Kasiske, B.L.1
Kalil, R.S.2
Ma, J.Z.3
-
101
-
-
0024324630
-
Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril
-
Heeg JE, de John PE, van der Hem GK et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989; 36:272-9.
-
(1989)
Kidney Int
, vol.36
, pp. 272-279
-
-
Heeg, J.E.1
De John, P.E.2
Van Der Hem, G.K.3
-
102
-
-
0035165760
-
Clinical practice recommendations 2001. Diabetic nephropathy
-
American Diabetes Association. Clinical practice recommendations 2001. Diabetic nephropathy. Diabetes Care. 2001; 24(suppl 1):S69-72.
-
(2001)
Diabetes Care
, vol.24
, Issue.1 SUPPL.
-
-
-
103
-
-
0033852481
-
Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group
-
Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36:646-61.
-
(2000)
Am J Kidney Dis
, vol.36
, pp. 646-661
-
-
Bakris, G.L.1
Williams, M.2
Dworkin, L.3
-
104
-
-
0026657559
-
Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
-
Lafayette RA, Mayer G, Park SK et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992; 90:766-71.
-
(1992)
J Clin Invest
, vol.90
, pp. 766-771
-
-
Lafayette, R.A.1
Mayer, G.2
Park, S.K.3
-
105
-
-
0031595541
-
Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage
-
Nishikawa K. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens. 1998; 12:301-9.
-
(1998)
J Hum Hypertens
, vol.12
, pp. 301-309
-
-
Nishikawa, K.1
-
106
-
-
0027633488
-
Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes
-
Remuzzi A, Perico N, Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol. 1993; 4:40-9.
-
(1993)
J Am Soc Nephrol
, vol.4
, pp. 40-49
-
-
Remuzzi, A.1
Perico, N.2
Amuchastegui, C.S.3
-
107
-
-
0031304268
-
Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus
-
O'Donnell MP, Crary GS, Oda H et al. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int Suppl. 1997; 63:S218-20.
-
(1997)
Kidney Int Suppl
, vol.63
-
-
O'Donnell, M.P.1
Crary, G.S.2
Oda, H.3
-
108
-
-
0028130636
-
Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury
-
Kim S, Ohta K, Hamaguchi A et al. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int. 1994; 46:1346-58.
-
(1994)
Kidney Int
, vol.46
, pp. 1346-1358
-
-
Kim, S.1
Ohta, K.2
Hamaguchi, A.3
-
109
-
-
0031605321
-
Role of AT1 angiotensin II receptors in renal ischemic injury
-
Kontogiannis J, Burns KD. Role of AT1 angiotensin II receptors in renal ischemic injury. Am J Physiol. 1998; 274:F79-90.
-
(1998)
Am J Physiol
, vol.274
-
-
Kontogiannis, J.1
Burns, K.D.2
-
110
-
-
0031890736
-
Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation
-
Ots M, Mackenzie HS, Troy JL et al. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol. 1998; 9:224-30.
-
(1998)
J Am Soc Nephrol
, vol.9
, pp. 224-230
-
-
Ots, M.1
Mackenzie, H.S.2
Troy, J.L.3
-
111
-
-
0031049715
-
Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
-
Oikawa T, Freeman M, Lo W et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997; 51:164-72.
-
(1997)
Kidney Int
, vol.51
, pp. 164-172
-
-
Oikawa, T.1
Freeman, M.2
Lo, W.3
-
112
-
-
0028335425
-
Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease
-
Gansevoort RT, de Zeeuw D, Shahinfar S et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl 1994; 12:S37-42.
-
(1994)
J Hypertens Suppl
, vol.12
-
-
Gansevoort, R.T.1
De Zeeuw, D.2
Shahinfar, S.3
-
113
-
-
0028295765
-
Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
-
Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994; 45:861-7.
-
(1994)
Kidney Int
, vol.45
, pp. 861-867
-
-
Gansevoort, R.T.1
De Zeeuw, D.2
De Jong, P.E.3
-
114
-
-
0030757514
-
Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study
-
Nielsen S, Dollerop J, Nielsen B et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant. 1997; 12(suppl 2):19-23.
-
(1997)
Nephrol Dial Transplant
, vol.12
, Issue.2 SUPPL.
, pp. 19-23
-
-
Nielsen, S.1
Dollerop, J.2
Nielsen, B.3
-
115
-
-
0030658031
-
Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes
-
Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens. 1997; 11(suppl 2):S81-3.
-
(1997)
J Hum Hypertens
, vol.11
, Issue.2 SUPPL.
-
-
Trenkwalder, P.1
Lehtovirta, M.2
Dahl, K.3
-
116
-
-
0031424634
-
A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers
-
Tillman HC, Walker RJ, Lewis-Barned NJ et al. A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers. J Clin Pharm Ther. 1997; 22:273-8.
-
(1997)
J Clin Pharm Ther
, vol.22
, pp. 273-278
-
-
Tillman, H.C.1
Walker, R.J.2
Lewis-Barned, N.J.3
-
117
-
-
0034057595
-
Insulin sensitivity in hypertensive type 2 diabetic patients after 1 and 19 days' treatment with trandolapril
-
New JP, Bilous RW, Walker M. Insulin sensitivity in hypertensive type 2 diabetic patients after 1 and 19 days' treatment with trandolapril. Diabet Med. 2000; 17:134-40.
-
(2000)
Diabet Med
, vol.17
, pp. 134-140
-
-
New, J.P.1
Bilous, R.W.2
Walker, M.3
-
118
-
-
0031766034
-
Captopril does not improve insulin action in essential hypertension: A double-blind placebo-controlled study
-
Wiggam MI, Hunter SJ, Atkinson AB et al. Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens. 1998; 16:1651-7.
-
(1998)
J Hypertens
, vol.16
, pp. 1651-1657
-
-
Wiggam, M.I.1
Hunter, S.J.2
Atkinson, A.B.3
-
119
-
-
0032810189
-
Insulin sensitivity in patients with essential hypertension: No influence of the ACE inhibitor enalapril
-
Heise T, Heinemann L, Kristahn K et al. Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. Horm Metal Res. 1999; 31:418-23.
-
(1999)
Horm Metal Res
, vol.31
, pp. 418-423
-
-
Heise, T.1
Heinemann, L.2
Kristahn, K.3
-
120
-
-
0031763235
-
Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of nondiabetic hypertensive patients
-
Fogari R, Zoppi A, Corradi L et al. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of nondiabetic hypertensive patients. Br J Clin Pharmacol. 1998; 46:467-71.
-
(1998)
Br J Clin Pharmacol
, vol.46
, pp. 467-471
-
-
Fogari, R.1
Zoppi, A.2
Corradi, L.3
-
121
-
-
0033056519
-
Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities
-
Nakagawa H, Daihara M, Tamakawa H et al. Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. J Cardiovasc Pharmacol. 1999; 34: 28-33.
-
(1999)
J Cardiovasc Pharmacol
, vol.34
, pp. 28-33
-
-
Nakagawa, H.1
Daihara, M.2
Tamakawa, H.3
|